Androstanazole
Androstanazole is a pyrazole-fused dihydrotestosterone derivative belonging to the same heterocyclic-steroid family as stanozolol, described in older medicinal-chemistry literature as an orally active anabolic candidate. Human data are essentially absent and it is of historical/chemical interest.
01 Overview
Androstanazole is one of several A-ring pyrazole-fused androstane steroids explored during the mid-20th-century search for orally active anabolics, the most successful of which was stanozolol. The fused pyrazole ring confers oral activity and non-aromatisable behaviour.
Unlike stanozolol, androstanazole never reached significant clinical or commercial use, and the compound survives mainly in structure-activity surveys. Its expected profile is inferred from the pyrazole-androstane class rather than from dedicated human study.
02 Mechanism
Androgen-receptor agonist; an A-ring pyrazole-fused 5-alpha-androstane derivative giving oral bioavailability and resistance to aromatisation.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Historical (inferred) | 5–20 mg/day | Oral | Inferred from stanozolol-class dosing; no established human range. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Anabolic activityAnabolic action inferred from pyrazole-androstane structure; unconfirmed in humans. | unquantified | Preclinical | |
| Low estrogenic activityDoes not aromatise, so estrogenic effects are minimal. | non-aromatising | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HepatotoxicityHepatic strain anticipated for an oral heterocyclic androgen. | Moderate | Class effect | Preclinical | |
| HPTA suppressionSuppression of endogenous testosterone. | Moderate | Expected | Preclinical |